{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:08:13Z","timestamp":1788826093573,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1016\/j.vaccine.2006.09.025","type":"journal-article","created":{"date-parts":[[2006,9,21]],"date-time":"2006-09-21T11:29:52Z","timestamp":1158838192000},"page":"2491-2496","source":"Crossref","is-referenced-by-count":51,"title":["Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs"],"prefix":"10.1016","volume":"25","author":[{"given":"Germie P.J.M.","family":"van den Dobbelsteen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry H.","family":"van Dijken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subramonia","family":"Pillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loek","family":"van Alphen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2006.09.025_bib1","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1086\/313608","article-title":"Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I","volume":"30","author":"Hausdorff","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2006.09.025_bib2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1473-3099(04)01251-4","article-title":"Meningococcal polysaccharide\u2013protein conjugate vaccines","volume":"5","author":"Snape","year":"2005","journal-title":"Lancet Infet Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2006.09.025_bib3","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00006454-200003000-00003","article-title":"Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group","volume":"19","author":"Black","year":"2000","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2006.09.025_bib4","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM200102083440602","article-title":"Efficacy of a pneumococcal conjugate vaccine against acute otitis media","volume":"344","author":"Eskola","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2006.09.025_bib5","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/01.inf.0000129685.04847.94","article-title":"Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente","volume":"23","author":"Black","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2006.09.025_bib6","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection-serum bactericidal antibody activity","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.09.025_bib7","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/0264-410X(95)98264-B","article-title":"Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane vesicle vaccine","volume":"13","author":"van der Ley","year":"1995","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.09.025_bib8","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/0264-410X(96)00020-5","article-title":"Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine","volume":"14","author":"Claassen","year":"1996","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.09.025_bib9","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1016\/S0264-410X(99)00044-4","article-title":"Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins","volume":"17","author":"Cartwright","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.09.025_bib10","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/S0264-410X(99)00423-5","article-title":"Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children 2\u20133 and 7\u20138 years of age","volume":"18","author":"De Kleijn","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.09.025_bib11","series-title":"Proceedings of the 14th International Pathogenic Neisseria Conference","first-page":"153","article-title":"From HexaMen to NonaMen: expanding a multivalent PorA-based meningococcal outer membrane vesicle vaccine","author":"Van den Dobbelsteen","year":"2004"},{"key":"10.1016\/j.vaccine.2006.09.025_bib12","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/S0264-410X(98)00129-7","article-title":"Immunogenicity of Streptococcus pneumoniae type 6B and 14 polysaccharide-tetanus toxoid conjugates and the effect of uncoupled polysaccharide on the antigen-specific immune response","volume":"16","author":"Rodriguez","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.09.025_bib13","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.1128\/IAI.71.11.6367-6371.2003","article-title":"Relative immunogenicity of PorA subtypes in a multivalent Neisseria meningitidis vaccine is not dependent on presentation form","volume":"71","author":"Luijkx","year":"2003","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2006.09.025_bib14","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/0264-410X(96)00001-1","article-title":"Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine","volume":"14","author":"Peeters","year":"1996","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.09.025_bib15","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0264-410X(96)00145-4","article-title":"Single shot with tetanus toxoid in biodegradable microspheres protects mice despite acid-induced denaturation of the antigen","volume":"14","author":"Kersten","year":"1996","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.09.025_bib16","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0022-1759(90)90264-V","article-title":"An ELISA employing a Haemophilus influenzae type b oligosaccharide-human serum albumin conjugate correlates with the radioantigen-binding assay","volume":"135","author":"Phipps","year":"1990","journal-title":"J Immunol Meth"},{"key":"10.1016\/j.vaccine.2006.09.025_bib17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2165\/00019053-200624020-00004","article-title":"Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands","volume":"24","author":"Bos","year":"2006","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.vaccine.2006.09.025_bib18","doi-asserted-by":"crossref","first-page":"5981","DOI":"10.1128\/IAI.69.10.5981-5990.2001","article-title":"Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity","volume":"69","author":"van der Ley","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2006.09.025_bib19","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1128\/CDLI.12.5.599-605.2005","article-title":"Combined administration of a meningococcal serogroup B outer membrane vesicle (OMV) vaccine and a conjugated serogroup C vaccine indicated for prevention of meningococcal disease is safe and immunogenic","volume":"12","author":"Aaberge","year":"2005","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2006.09.025_bib20","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/01.inf.0000151022.92222.be","article-title":"Immunogenicity and tolerability of a heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 12 months of age","volume":"24","author":"Kayhty","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2006.09.025_bib21","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/01.inf.0000207483.60267.e7","article-title":"Immunogenicity and boosting following a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers","volume":"25","author":"Goldblatt","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2006.09.025_bib22","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1001\/jama.293.14.1751","article-title":"Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: a randomized controlled trial","volume":"293","author":"Buttery","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2006.09.025_bib23","doi-asserted-by":"crossref","first-page":"5383","DOI":"10.1128\/IAI.72.9.5383-5391.2004","article-title":"Reduction of antibody response to an 11-valent pneumococcal vaccine coadministered with a vaccine containing acellular pertussis components","volume":"72","author":"Dagan","year":"2004","journal-title":"Infect Immun"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X06010279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X06010279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,18]],"date-time":"2020-04-18T08:50:15Z","timestamp":1587199815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X06010279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":23,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["S0264410X06010279"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2006.09.025","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2007,3]]}}}